Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 50
Summary
- Conditions
- Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
- Bladder Cancer
- Colo-rectal Cancer
- Esophageal Cancer
- Fallopian Tube Cancer
- Gastric Cancer
- Head and Neck Cancer Squamous Cell Carcinoma
- Renal Cell Carcinoma
- Melanoma
- Non -Small Cell Lung Cancer
- Ovarian Cancer
- Pancreas Cancer
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a Phase 1b, multi-center, open-label study with a dose-escalation part and a dose expansion part. The duration of the study participation for each patient is defined as the time from the date of signed written informed consent to the completion of the follow-up period, withdrawal of consent,...
This is a Phase 1b, multi-center, open-label study with a dose-escalation part and a dose expansion part. The duration of the study participation for each patient is defined as the time from the date of signed written informed consent to the completion of the follow-up period, withdrawal of consent, loss to follow-up, or death, whichever occurs first. The study will include a Screening Period (of up to 21 days), a Treatment Period (with cycles of 3 weeks for a Q3W dosing regimen), and a Follow-up Period (approximately every 12 week visits) for up to 1 year after treatment discontinuation
Tracking Information
- NCT #
- NCT03621982
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon